Gyre Therapeutics (GYRE)

ETUARY is a core commercial product for the company and is associated with the treatment of fibrotic disease. Gyre’s marketed portfolio also includes products such as avatrombopag and nintedanib, giving it exposure to therapies used in serious chronic conditions. This commercial base helps distinguish Gyre from purely development-stage biotechnology companies, because it has existing product sales alongside its research pipeline.

The company’s main development focus is Hydronidone, also known as F351, for metabolic dysfunction-associated steatohepatitis-related liver fibrosis. MASH fibrosis is a large and difficult-to-treat disease area linked to metabolic dysfunction and progressive liver damage. Successful development in this indication could be significant, but it also requires clinical evidence, regulatory approval, and commercial execution in a competitive therapeutic field.

Gyre is also advancing additional candidates in China, including F573, F528, and F230, broadening its pipeline across fibrosis and inflammation-related opportunities. For investors following GYRE, the key factors are sales performance of its existing products, clinical progress for Hydronidone, regulatory developments in China and other target markets, and the company’s ability to translate fibrosis expertise into approved, differentiated therapies.